Hydrocinnamic acidCAS# 501-52-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 501-52-0 | SDF | Download SDF |
| PubChem ID | 107 | Appearance | Powder |
| Formula | C9H10O2 | M.Wt | 150.2 |
| Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-phenylpropanoic acid | ||
| SMILES | C1=CC=C(C=C1)CCC(=O)O | ||
| Standard InChIKey | XMIIGOLPHOKFCH-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C9H10O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H,10,11) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Hydrocinnamic acid inhibits the currents of WT and SQT3 syndrome-related mutants of Kir2.1 channel. |
Hydrocinnamic acid Dilution Calculator
Hydrocinnamic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.6578 mL | 33.2889 mL | 66.5779 mL | 133.1558 mL | 166.4447 mL |
| 5 mM | 1.3316 mL | 6.6578 mL | 13.3156 mL | 26.6312 mL | 33.2889 mL |
| 10 mM | 0.6658 mL | 3.3289 mL | 6.6578 mL | 13.3156 mL | 16.6445 mL |
| 50 mM | 0.1332 mL | 0.6658 mL | 1.3316 mL | 2.6631 mL | 3.3289 mL |
| 100 mM | 0.0666 mL | 0.3329 mL | 0.6658 mL | 1.3316 mL | 1.6644 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Resveratrol
Catalog No.:BCN5607
CAS No.:501-36-0
- 8-Azabicyclo-3.2.1-octan-3-ol
Catalog No.:BCN1888
CAS No.:501-33-7
- Kojic acid
Catalog No.:BCN6543
CAS No.:501-30-4
- Cardanol (C15:1)
Catalog No.:BCN3751
CAS No.:501-26-8
- Trans-caffeic acid
Catalog No.:BCN3462
CAS No.:501-16-6
- Securinol A
Catalog No.:BCN6987
CAS No.:5008-48-0
- GANT61
Catalog No.:BCC1090
CAS No.:500579-04-4
- Rilpivirine
Catalog No.:BCC1897
CAS No.:500287-72-9
- 3,5-Dimethoxyphenol
Catalog No.:BCN7198
CAS No.:500-99-2
- Olivetol
Catalog No.:BCN4629
CAS No.:500-66-3
- Rhapontigenin
Catalog No.:BCN3515
CAS No.:500-65-2
- Kawain
Catalog No.:BCN3564
CAS No.:500-64-1
- 2-(4-Hydroxyphenyl)ethanol
Catalog No.:BCN5608
CAS No.:501-94-0
- Rhododendrol
Catalog No.:BCN5609
CAS No.:501-96-2
- Phloretic acid
Catalog No.:BCN2950
CAS No.:501-97-3
- 2,3-Di-O-methylthiomethyleuscaphic acid
Catalog No.:BCN5610
CAS No.:
- Pilosol A
Catalog No.:BCC9121
CAS No.:501086-15-3
- 5,6,7,4'-Tetrahydroxyflavanone 6,7-diglucoside
Catalog No.:BCN1434
CAS No.:501434-65-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- NS 1738
Catalog No.:BCC7535
CAS No.:501684-93-1
- NSC 74859
Catalog No.:BCC3701
CAS No.:501919-59-1
- PNU-120596
Catalog No.:BCC4581
CAS No.:501925-31-1
- SB705498
Catalog No.:BCC3854
CAS No.:501951-42-4
- Lycopene
Catalog No.:BCN5410
CAS No.:502-65-8
Hydrocinnamic Acid Inhibits the Currents of WT and SQT3 Syndrome-Related Mutants of Kir2.1 Channel.[Pubmed:28660286]
J Membr Biol. 2017 Oct;250(5):425-432.
Gain of function in mutations, D172N and E299V, of Kir2.1 will induce type III short QT syndrome. In our previous work, we had identified that a mixture of traditional Chinese medicine, styrax, is a blocker of Kir2.1. Here, we determined a monomer, Hydrocinnamic acid (HA), as the effective component from 18 compounds of styrax. Our data show that HA can inhibit the currents of Kir2.1 channel in both excised inside-out and whole-cell patch with the IC50 of 5.21 +/- 1.02 and 10.08 +/- 0.46 mM, respectively. The time course of HA blockage and washout are 2.3 +/- 0.6 and 10.5 +/- 2.6 s in the excised inside-out patch. Moreover, HA can also abolish the currents of D172N and E299V with the IC50 of 6.66 +/- 0.57 and 5.81 +/- 1.10 mM for D172N and E299V, respectively. Molecular docking results determine that HA binds with Kir2.1 at K182, K185, and K188, which are phosphatidylinositol 4,5-bisphosphate (PIP2) binding residues. Our results indicate that HA competes with PIP2 to bind with Kir2.1 and inhibits the currents.
Salt effect on phenolics and antioxidant activities of Tunisian and Canadian sweet marjoram (Origanum majorana L.) shoots.[Pubmed:22674342]
J Sci Food Agric. 2013 Jan 15;93(1):134-41.
BACKGROUND: Two varieties of Origanum majorana (Canadian and Tunisian) were evaluated for their phenolic, flavonoid and tannin contents, individual phenolic compounds and antioxidant activities under NaCl constraint. RESULTS: The results showed a significant variability in phenolic composition and antioxidant behavior between the two varieties under salt stress. The phenolic composition of methanolic extracts was determined by reversed-phase high-performance liquid chromatography. Amentoflavone was the predominant flavonoid compound; in addition, trans-2-Hydrocinnamic acid became the major phenolic acid with salt treatment of the Tunisian variety. In the control, Canadian variety extract was characterized by high levels of gallic acid and amentoflavone. However, under 75 mmol L(-1) NaCl, gallic acid content doubled, whereas amentoflavone content was maintained in the Canadian variety. Stimulation of phenolic acid biosynthesis was observed in these two varieties under salt treatment despite the fact that shoots of the Tunisian variety showed higher antioxidant activities compared to those from the Canadian variety. Tunisian O. majorana might have developed tolerance to salinity and avoided tissue damage by activating enzymes involved in the galactosylation of quercetin into quercetin-3-galactoside and quercetin-3-rhamnoside. CONCLUSION: Our results confirmed the tolerance of Tunisian O. majorana plants.
